Anastrozole is a medication used for treatment of breast cancer. It is specifically used for hormone receptor-positive breast cancer. It has also been used to prevent breast cancer in those women who are at high risk of menopause. Anastrozole belongs to the aromatase-inhibiting drug class. In the World Health Organization's List of Essential Medicines, anastrozole is the safest and most effective medicine for breast cancer in menopausal women. Companies such as Dr. Reddy’s Laboratories, Teva Pharmaceutical Industries Ltd., AstraZeneca Plc, Accord Healthcare, Mylan N.V., and Sun Pharma Ltd. are the prominent players in the market. Anastrozole tablets are also used by bodybuilders and athletes to reduce the estrogen production that is a side effect of steroid use.
The anastrozole tablets market is estimated to be valued at US$ 278.1 million in 2020 and is expected to exhibit a CAGR of 2.8% over the forecast period (2020-2027).
Fig1. Anastrozole Tablets Market Share (%) Analysis, By Type, 2019
Increasing prevalence of breast cancer and increasing product launches are expected to drive growth of the anastrozole tablets market
The increasing prevalence of breast cancer in women is expected to significantly contribute to growth of the anastrozole tablets market growth over the forecast period. For instance, according to the World Cancer Research Fund (WCRF) report of 2018, breast cancer is the most commonly occurring cancer in women and the second most common cancer globally. There were over 2 million new cases in 2018, globally. Furthermore, according to the World Health Organization (WHO) report of 2018, it is estimated that 627,000 women died from breast cancer in 2018, worldwide.
Major players in the market are focused on launching anastrozole tablets in the market at low cost to gain maximum market share, which is expected to drive the anastrozole tablets market growth. For instance, in December 2013, Eli Lilly and Company, India announced that it launched four generic cancer drugs to treat patients with breast and colorectal cancer, respectively in India. The company launched four new drugs, Lilbecep (Epirubicin), Lilmantro (Anastrozole), Lilxapla (Oxaliplatin), and Lilrincan (Irinotecan), for the treatment of patients with breast cancer and colorectal cancer, respectively.
Anastrozole Tablets Market - Restraints
However, anastrozole tablets market growth is expected to hamper over the forecast period, owing to frequent drug recalls. For instance, in May 2019, Zydus Pharmaceuticals USA Inc. announced that it voluntarily recalled multiple lots of anastrozole tablets (1mg) at retail level. The product is under investigation by the U.S. FDA. The reason of drug recall was cross contamination due to a GMP cleaning procedure failure in the fluid bed dry processor area during the manufacturing time. Zydus Pharmaceuticals USA Inc. advised all the distributors to stop dispensing, which rapidly impeded growth of the anastrozole tablets market in 2019.
Anastrozole Tablets Market – Regional Analysis
North America accounted for the largest share in the anastrozole tablets market, followed by Europe in 2019, owing to increasing product launches. For instance, in February 2012, AstraZeneca Plc launched its first-ever direct-to-patient program offered to those with a valid prescription for breast cancer drug Arimidex (anastrozole) through a specialty pharmacy services provider in the U.S., for US$ 40 per month.
Furthermore, increasing launch of anastrozole tablets is also expected to boost the anastrozole tablets market growth in Asia Pacific in the near future. For instance, in September 2019, Cooper Pharma, a pharmaceutical manufacturing company specialized in generics/hormonal medications, announced that one of its wholly owned hormone product ANAZBOL was launched in New Delhi, India. The company is also set to launch ANAZBOL in 25 other countries with legal authorization.
Fig2. Anastrozole Tablets Market Value (US$ Mn) & Y-o-Y Growth (%), 2017-2027
Anastrozole Tablets Market - Competitive Landscape
Key players operating in the anastrozole tablets market include AstraZeneca Plc, Zydus Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Hikma Pharmaceuticals, Natco Pharma, Fresenius Kabi, Accord Healthcare Ltd., Mylan N.V., Cipla Ltd., Apotex Inc., Zhejiang Hisun, Chongqing Huapont Pharmaceutical Co., Ltd., Zhejiang Wansheng Pharmaceutical Co. Ltd., and Yangtze River Pharmaceutical Group.
Frequently Asked Questions